Er-Kim has announced that it has signed an agreement with Sentynl Therapeutics to distribute Nulibry and Zokinvy.
Nulibry and Zokinvy are the only EMA and FDA-approved treatments for their indicated conditions.
Through this collaboration, patients will gain access to these treatments in certain countries within Central and Eastern Europe, the Mediterranean region and throughout Eurasian markets.
Nulibry for injection is the only EMA and FDA-approved therapy to reduce mortality risk in patients with molybdenum cofactor deficiency (MoCD) Type A, a rare, life-threatening genetic, metabolic disorder that can cause severe neurological injury.
With symptoms often presenting at birth, MoCD progresses rapidly and if left untreated, it can cause premature death in children.
Similarly, Zokinvy is the sole approved treatment for Hutchinson-Gilford Progeria Syndrome (HGPS) and some types of Progeroid Laminopathies known as processing-deficient Progeroid Laminopathies (PDPL) in adult and paediatric patients 12 months of age and older.
These illnesses are caused when the body makes harmful proteins, which build up and lead to progressive premature ageing and heart problems usually seen in much older people.
Young people with Progeria age at a rapid rate, 8 to 10 times faster than healthy people of the same age.
The agreement covers the distribution of Nulibry and Zokinvy by Er-Kim in 33 countries, encompassing Poland, Greece, Turkey, Czechia, Romania, Kazakhstan and Russia, amongst others.
Cem Zorlular, CEO of Er-Kim, said, “Providing rare disease patients with timely access to life-altering medications is paramount, and we are proud to have consistently delivered treatments across a wide geographic area, ensuring they receive care concurrent with patients in the US and Western Europe."
"We are therefore thrilled to collaborate with Sentynl to bring Nulibry and Zokinvy to patients in these designated regions, offering a vital chance at improved lives."
"Er-Kim’s global expertise in the distribution of rare disease treatments globally drives our mission to expand drug accessibility through strategic partnerships.”
“The work we do is centred around developing therapies that extend, improve, or enhance the lives of people with rare diseases," said Matt Heck, CEO, Sentynl.
"This partnership is an important milestone and enables us to bring Nulibry and Zokinvy to more patients around the world."